title: Validation of putative genomic biomarkers of nephrotoxicity in rats.
abstract: Drug-induced renal injury is a common finding in the early preclinical phase of drug development. But the specific genes responding to renal injury remain poorly defined. Identification of drug-induced gene changes is critical to provide insights into molecular mechanisms and detection of renal damage. To identify genes associated with the development of drug-induced nephrotoxicity, a literature survey was conducted and a panel of 48 genes was selected based on gene expression changes in multiple published studies. Male Sprague-Dawley rats were dosed daily for 1, 3 or 5 days to the known nephrotoxicants gentamicin, bacitracin, vancomycin and cisplatin, or the known hepatotoxicants ketoconazole, 1-naphthyl isothiocyanate and 4,4-diaminodiphenylmethane. Histopathological evaluation and clinical chemistry revealed renal proximal tubular necrosis in rats treated with the nephrotoxicants, but not from those treated with the hepatotoxicants. RNA was extracted from the kidney, and RT-PCR was performed to evaluate expression profiles of the selected genes. Among the genes examined, 24 genes are confirmed to be highly induced or repressed in rats treated with nephrotoxicants; further investigation identified that 5 of the 24 genes were also altered by hepatotoxicants. These data led to the identification of a set of genomic biomarker candidates whose expression in kidney is selectively regulated only by nephrotoxicants. Among those genes displaying the highest expression changes specifically in nephrotoxicant-treated rats were kidney injury molecule 1 (Kim1), lipocalin 2 (Lcn2), and osteopontin (Spp1). The establishment of such a genomic marker set offers a new tool in our ongoing quest to monitor nephrotoxicity.
authors.affiliation: Department of Genetic and Molecular Toxicology, Drug Safety and Metabolism Division, Schering-Plough Corporation, Summit, NJ 07901, USA.
authors.forename: Er-Jia
authors.initials: EJ
authors.lastname: Wang
authors.forename: Ronald D
authors.initials: RD
authors.lastname: Snyder
authors.forename: Mark R
authors.initials: MR
authors.lastname: Fielden
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Smith
authors.forename: Yi-Zhong
authors.initials: YZ
authors.lastname: Gu
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000633:toxicity*; D000970:Antineoplastic Agents / Q000633:toxicity*; D001414:Bacitracin / Q000633:toxicity; D002945:Cisplatin / Q000633:toxicity; D015870:Gene Expression / Q000235:genetics; D020869:Gene Expression Profiling; D005819:Genetic Markers; D005839:Gentamicins / Q000633:toxicity; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D043922:Toxicogenetics; D014640:Vancomycin / Q000633:toxicity
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D005819:Genetic Markers; D005839:Gentamicins; D012333:RNA, Messenger; D001414:Bacitracin; D014640:Vancomycin; D002945:Cisplatin